Assess whether the 505(b)(2) bridge is legally and scientifically enough

SITUATION After a site-change that invalidates stability claims, RWE protocol that may not meet regulator expectations is what labeling negotiator can touch in an RWE group proposing a post-marketing study instead of a new RCT. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this Clinical and Evidence Strategy file.

DECISION Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; RWE protocol that may not meet regulator expectations already has the discriminator after a site-change that invalidates stability claims. 2. Keep Pause the pathway in force until RWE protocol that may not meet regulator expectations is completed after a site-change that invalidates stability claims for labeling negotiator. 3. Treat RWE protocol that may not meet regulator expectations as Escalate safety review because both readings appear after a site-change that invalidates stability claims. 4. Refuse a Pharma & Life Sciences close: labeling negotiator does not have the decision the 505(b)(2) bridge is turns on in RWE protocol that may not meet regulator expectations.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 2. Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against a site-change that invalidates stability claims and write the one fact that would move the 505(b)(2) bridge is for labeling negotiator.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on the 505(b)(2) bridge is, then the evidence in RWE protocol that may not meet regulator expectations, then the action for labeling negotiator - Hypothesis scorecard against RWE protocol that may not meet regulator expectations: supported / rejected / untestable - Clinical and Evidence Strategy finding in RWE protocol that may not meet regulator expectations that a second reviewer can re-perform - Missing page in RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims, if any